Cargando…

Sustained Low Relapse Rate With Highly Variable B-Cell Repopulation Dynamics With Extended Rituximab Dosing Intervals in Multiple Sclerosis

BACKGROUND AND OBJECTIVES: B cell–depleting therapies are highly effective in relapsing-remitting multiple sclerosis (RRMS) but are associated with increased infection risk and blunted humoral vaccination responses. Extension of dosing intervals may mitigate such negative effects, but its consequenc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Starvaggi Cucuzza, Chiara, Longinetti, Elisa, Ruffin, Nicolas, Evertsson, Björn, Kockum, Ingrid, Jagodic, Maja, Al Nimer, Faiez, Frisell, Thomas, Piehl, Fredrik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9749930/ https://www.ncbi.nlm.nih.gov/pubmed/36411076 http://dx.doi.org/10.1212/NXI.0000000000200056

Ejemplares similares

B‐cell repopulation dynamics and drug pharmacokinetics impact SARS‐CoV‐2 vaccine efficacy in anti‐CD20‐treated multiple sclerosis patients
por: Asplund Högelin, Klara, et al.
Publicado: (2022)

A comparative study of tolerability and effects on immunoglobulin levels and CD19 cell counts with ocrelizumab vs low dose of rituximab in multiple sclerosis
por: Evertsson, Björn, et al.
Publicado: (2020)

Therapeutic efficacy of dimethyl fumarate in relapsing-remitting multiple sclerosis associates with ROS pathway in monocytes
por: Carlström, Karl E., et al.
Publicado: (2019)

Risk of depression in multiple sclerosis across disease-modifying therapies
por: Longinetti, Elisa, et al.
Publicado: (2021)

Diagnostic accuracy of intrathecal kappa free light chains compared with OCBs in MS
por: Duell, Frida, et al.
Publicado: (2020)

Small noncoding RNA profiling across cellular and biofluid compartments and their implications for multiple sclerosis immunopathology
por: Zheleznyakova, Galina Yurevna, et al.
Publicado: (2021)

Disease activity in pregnancy and postpartum in women with MS who suspended rituximab and natalizumab
por: Razaz, Neda, et al.
Publicado: (2020)

Rituximab Infusion Timing, Cumulative Dose, and Hospitalization for COVID-19 in Persons With Multiple Sclerosis in Sweden
por: McKay, Kyla A., et al.
Publicado: (2021)

Early B cells repopulation in multiple sclerosis patients treated with rituximab is not predictive of a risk of relapse or clinical progression
por: Dorcet, Guillaume, et al.
Publicado: (2022)

Susceptibility to Oxidative Stress Is Determined by Genetic Background in Neuronal Cell Cultures
por: Günther, Mattias, et al.
Publicado: (2018)

Demographic and disease‐related factors impact on cerebrospinal fluid neurofilament light chain levels in multiple sclerosis
por: Zondra Revendova, Kamila, et al.
Publicado: (2022)

Extended interval dosing of ocrelizumab modifies the repopulation of B cells without altering the clinical efficacy in multiple sclerosis
por: Rodriguez-Mogeda, Carla, et al.
Publicado: (2023)

Copy number variations across the blood–brain barrier in multiple sclerosis
por: Bedri, Sahl Khalid, et al.
Publicado: (2022)

Development of humoral and cellular immunological memory against SARS-CoV-2 despite B cell depleting treatment in multiple sclerosis
por: Asplund Högelin, Klara, et al.
Publicado: (2021)

Case Report: Efficacy of Rituximab in a Patient With Familial Mediterranean Fever and Multiple Sclerosis
por: Pozzato, Mattia, et al.
Publicado: (2021)

Efficacy of Rituximab Outlasts B-Cell Repopulation in Multiple Sclerosis: Time to Rethink Dosing?
por: Claverie, Roxane, et al.
Publicado: (2023)

Low-dose rituximab should be used for treating MS in resource-limited settings: Yes
por: Piehl, Fredrik, et al.
Publicado: (2022)

Clinical impact of Ocrelizumab extended interval dosing during the COVID-19 pandemic and associations with CD19(+)B-cell repopulation
por: Sahi, Nitin Kumar, et al.
Publicado: (2021)

Rituximab, MS, and pregnancy
por: Smith, Jessica B., et al.
Publicado: (2020)

Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond?
por: Maarouf, Adil, et al.
Publicado: (2020)

Regucalcin Expression in Bovine Tissues and Its Regulation by Sex Steroid Hormones in Accessory Sex Glands
por: Starvaggi Cucuzza, Laura, et al.
Publicado: (2014)

Competitive repopulation of an empty microglial niche yields functionally distinct subsets of microglia-like cells
por: Lund, Harald, et al.
Publicado: (2018)

Validation of the Swedish Multiple Sclerosis Register: Further Improving a Resource for Pharmacoepidemiologic Evaluations
por: Alping, Peter, et al.
Publicado: (2019)

The Problem of Repopulation
Publicado: (1917)

Circulating miR-150 in CSF is a novel candidate biomarker for multiple sclerosis
por: Bergman, Petra, et al.
Publicado: (2016)

17β-estradiol upregulates oxytocin and the oxytocin receptor in C2C12 myotubes
por: Berio, Enrica, et al.
Publicado: (2017)

Confounding effect of blood volume and body mass index on blood neurofilament light chain levels
por: Manouchehrinia, Ali, et al.
Publicado: (2020)

Assessing the Preanalytical Variability of Plasma and Cerebrospinal Fluid Processing and Its Effects on Inflammation-Related Protein Biomarkers
por: Huang, Jesse, et al.
Publicado: (2021)

Safety of Alemtuzumab and Autologous Hematopoietic Stem Cell Transplantation Compared to Noninduction Therapies for Multiple Sclerosis
por: Alping, Peter, et al.
Publicado: (2021)

Repopulation of T, B, and NK cells following alemtuzumab treatment in relapsing-remitting multiple sclerosis
por: Gilmore, Wendy, et al.
Publicado: (2020)

Comparative Assessment of the Prognostic Value of Biomarkers in Traumatic Brain Injury Reveals an Independent Role for Serum Levels of Neurofilament Light
por: Al Nimer, Faiez, et al.
Publicado: (2015)

Non-parametric combination analysis of multiple data types enables detection of novel regulatory mechanisms in T cells of multiple sclerosis patients
por: Fernandes, Sunjay Jude, et al.
Publicado: (2019)

Efficacy and Safety of Rituximab for New-Onset Generalized Myasthenia Gravis: The RINOMAX Randomized Clinical Trial
por: Piehl, Fredrik, et al.
Publicado: (2022)

Delayed B cell repopulation after rituximab treatment in multiple sclerosis patients with expanded adaptive natural killer cells
por: Moreira, Antía, et al.
Publicado: (2022)

Characterization of More Selective Central Nervous System Nrf2-Activating Novel Vinyl Sulfoximine Compounds Compared to Dimethyl Fumarate
por: Carlström, Karl E., et al.
Publicado: (2020)

Fluid proteomics of CSF and serum reveal important neuroinflammatory proteins in blood–brain barrier disruption and outcome prediction following severe traumatic brain injury: a prospective, observational study
por: Lindblad, Caroline, et al.
Publicado: (2021)

Neurodegenerative and psychiatric diseases among families with amyotrophic lateral sclerosis
por: Longinetti, Elisa, et al.
Publicado: (2017)

Variability in C-type lectin receptors regulates neuropathic pain-like behavior after peripheral nerve injury
por: Dominguez, Cecilia A, et al.
Publicado: (2014)

Neutralizing Anti-Rituximab Antibodies and Relapse in Membranous Nephropathy Treated With Rituximab
por: Boyer-Suavet, Sonia, et al.
Publicado: (2020)

Persistence with dimethyl fumarate in relapsing-remitting multiple sclerosis: a population-based cohort study
por: Eriksson, Irene, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_3use53b60i349sfhgiq5euf4h6